Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects

The aims of this randomized, double‐blind, three‐arm, single‐dose study were to demonstrate pharmacokinetic (PK) equivalence of the adalimumab biosimilar M923 (hereafter referred to as “M923”) to each of 2 reference products, and to assess M923's safety and immunogenicity. Primary PK endpoints...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacol Res Perspect
Hlavní autoři: Hillson, Jan, Mant, Tim, Rosano, Molly, Huntenburg, Carolyn, Alai‐Safar, Mehrshid, Darne, Siddhesh, Palmer, Donna, Pavlova, Borislava G., Doralt, Jennifer, Reeve, Russell, Goel, Niti, Weilert, Doris, Rhyne, Paul W., Chance, Kamali, Caminis, John, Roach, James, Ganguly, Tanmoy
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5817835/
https://ncbi.nlm.nih.gov/pubmed/29417761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.380
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky